Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/13566
標題: 硫代乙醯氨致大鼠肝硬化與胰島素阻抗之研究
Study of Thioacetamide Induced Liver Cirrhosis and Insulin Resistance in Rat
作者: 褚建宇
Chu, Chien-Yu
關鍵字: thioacetamide;thioacetamide;silymarin;liver cirrhosis;insulin resistance;silymarin;肝硬化;胰島素阻抗
出版社: 獸醫學系暨研究所
引用: 1.Anderson RA. Chromium as an essential nutrient for humans. Regul Toxicol Pharmacol 26: S35-S41, 1997. 2.Andreelli F, Laville M, Vega N, Riou JP, Vidal H. Regulation of gene expression during severe caloric restriction: lack of induction of p85 alpha phosphatidylinostiol 3-kinase mRNA in skeletal muscle of patients with type II(non-insulin dependent) diabetes mellitus. Diabetologia 43: 353-363, 2000. 3.Arner P, Pollare T, Lithell H, Livingston JN. Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30(6): 437-440, 1987. 4.Ariosto F, Riggio O, Cantafora A, Colucci S, Gaudio E, Mechelli C. Carbon tetrachloride-induced experimental cirrhosis in rat: a reappraisal of the model. Eur Surg Res 21: 280-286, 1989. 5.Arthur MJ. Fibrogenesis II. Metalloproteinasesand their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 279: G245-G249, 2000. 6.Barker EA and Smuckler EA. Altered microsome function during acute thioacetamide poisoning. Mol Pharmacol 8: 318-326, 1972. 7.Bataller R, Ginès P, Nicolás JM, Görbig MN, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V, Rodés J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118: 1149-1156, 2000. 8.Bataller R, Gäbele E, Schoonhoven R, Morris T, Lehnert M, Yang L, Brenner DA, Rippe RA. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol 285: G642-G651, 2003. 9.Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, Qian T, Schoonhoven R, Hagedorn CH, Lemasters JJ, and Brenner DA. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 112: 1383-1394, 2003. 10.Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 126: 529-540, 2004. 11.Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 115: 209-218, 2005. 12.Benyon RC, and Iredale JP. Is liver fibrosisreversible? Gut 46: 443-446, 2000. 13.Boya P, Larrea E, Sola I, Majano PL, Jiménez C, Civeira MP, Prieto J. Nuclear factor-kappa B in the liver of patients with chronic hepatitis C: decreased RelA expression is associated with enhanced fibrosis progression. Hepatology 34: 1041-1048, 2001. 14.Brautigan DL, Kruszewski A, Wang H. Chromium and vanadate combination increases insulin-induced glucose uptake by 3T3-L1 adipocytes. Biochem Biophys Res Commun 347: 769-773, 2006. 15.Casini A, Ceni E, Salzano R, Biondi P, Parola M, Galli A, Foschi M, Caligiuri A, Pinzani M, Surrenti C. Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. Hepatology. 25: 361-367, 1997. 16.Chang LM, Mao FC, Tai TY. Effect of chromium chloride GRT milk powder supplement on gene expression of insulin signaling molecules in KK/HIJ diabetic mice. 25th Annual Meeting The Endocrinology Society & Diabetes Association of the Republic of China 89, 2004. 17.Cheatham B and Kahn CR. Insulin action and the insulin signaling network. Endocr Rev 16: 117-142, 1995. 18.Chieli E and Malvaldi G. Role of the microsomal FAD-containing monooxygenase in the liver toxicity of thioacetamide-S-oxide. Toxicology 31: 41-51, 1984. 19.Chilakapati J, Shankar K, Korrapati MC, Hill RA, Mahendale HM. Saturation toxicokinetics of thioacetamide: role in initiation of liver injury. Drug Metab Dispos 33: 1877-1885, 2005. 20.Colombato LA, Robin M, Pomier-Layrargues G, Huet PM. Animal models of portal hypertension. Portal Hypertension- Proceedings of the 79th Falk Symposium. Germany: Kluwer Academic Publishers: 3-14,1995. 21.Cusi K, Maezono K, Osman A, Pendegrass M, Patti ME, Pratipanawate T, DeFronzo RA,Kahn CR, Mandarino LJ. Insulin resistance differentially affects the PI3-kinase and MAP-kinase-mediated signaling in human muscle. J Clin Invest 105: 311-320, 2000. 22.Damsbo P, Vaag A, Hother-Nielsen O, Beck-Nielsen H. Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 34: 239-245, 1991. 23.Dashti H, Jeppsson B,Hagerstrand I, Hultberg B, Srinivas U,Abdulla M Bengmark S. Thioacetamide- and carbon tetrachloride- induced liver cirrhosis. Eur Surg Res 21: 83-91, 1989. 24.Davis CM, Vicent JB. Chromium oligopeptide activites insulin receptor tyrosine kinase activity. Biochemistry 36: 4382-4385, 1997. 25.Desmet V, Roskams T, Eyken PV. Ductular reaction in the liver. Path Res Pract 191, 513-524, 1995. 26.Dooley S, Hamzavi J, Breitkopf K, Wiercinska E, Said HM, Lorenzen J, Ten Dijke P, Gressner AM. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 125: 178-191, 2003. 27.Ekström G, Ingelman-Sundberg M. Rat-liver microsomal NADPH supported oxidase activity and lipid-peroxidation dependent on ethanolinducible cytochrome-P-450 (P-450IIE1). Biochem Pharmacol 38: 1313-1319, 1989. 28.Faulstich H, Jahn W, Wieland T. Silybin inhibition of amatoxin uptake in the perfused rat liver. Arzneimittelforschung 30: 91-98, 1980. 29.Franco D, Gigou M, Szekely AM, Bismuth H. Portal hypertension after bile duct obstruction: effect of bile diversion on portal pressure in the rat. Arch Surg 114: 1064-1067, 1979. 30.Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PN. The protein kinase encoded by the Akt proto-oncogene isa target of the PDGF-activated phosphatidylinostitol 3-kinase. Cell 81: 727-736, 1995. 31.Friedman SL. Liver cirrhosis- from bench to bedside. J Hepatol 38: S38-S53, 2003. 32.Gabele E, Brenner DA, and Rippe RA. Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. Front Biosci 8: D69-D77, 2003. 33.Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, Ridolfi F, Trozzi L, Surrenti C, Casini A. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122: 1924-1940, 2002. 34.Garvey WT, Maianu L, Huecksteadt TP, Birnbaum MJ, Molina JM, Ciaraldi TP. Pretranslational suppression of glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity. J Clin Invest 87: 1072-1081, 1991. 35.Gebhardt R. Oxidative stress, plant-derived antioxidants and liver fibrosis. Planta Med 68: 289-296, 2002. 36.Goodyear LJ, Giorgino F, Sherman LA, Carey J, Smith RJ, Dohm GL. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 95: 2195-2204, 1995. 37.Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 7: d793-d807, 2002. 38.Higuchi H and Gores GJ. Mechanisms of liver injury: an overview. Curr Mol Med 3: 483-490, 2003. 39.Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95: 2409-2415, 1995. 40.Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271: 665- 668, 1996. 41.Huang C, Thirone AC, Huang X, Klip A. Differential contribution of IRS-1 vs. IRS-2 to insulin signaling and glucose uptake in L6 myotubes. J Biol Chem 280: 19426 -19435, 2005. 42.Hubbard SR. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 16: 5572-5581, 1997. 43.Hunter AL, Holscher MA, Neal RA. Thioacetamide-induced hepatic necrosis I: involvement of the mixed-function oxidase enzyme system. J Pharmacol Exp Ther 200: 439-448, 1977. 44.Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T, Fukuda T, Yamashina S, Kitamura T, Sato N. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 122: 1399-1410, 2002. 45.Jeejeebhoy KN, Chu RC, Marliss EB, Greenberg GR, Bruce-Robertson A. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr 123: 626-633, 1993. 46.Joshson VJ, Osuchowski MF, He Q, Sharman RP. Physiological responses to a natural antioxidant flavonoids mixture, silymarin, in BALB/c mice: II. Alterations on thymic differentiation correlate with changes in c-mycgene expression. Planta Med 68: 289-296, 2002. 47.Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, Fukui K, Maeda N, Nishizawa H, Nagaretani H, Okamoto Y, Kihara S, Miyagawa J, Shinomura Y, Funahashi T & Matsuzawa Y. Enhanced carbon tetrachloride- induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125: 1796-1807, 2003. 48.Kinnman N, Hultcrantz R, Barbu V, Rey C, Wendum D, Poupon R, Housset C. PDGF-mediated chemoattraction of hepativ stellate cells by bile duct segments in cholestatic liver injury. Lab Invest 80: 697-707, 2000. 49.Knittel T, Kobold D, Saile B, Grundmann A, Neubauer K, Piscaglia F, Ramadori G. Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 117: 1205-1221, 1999. 50.Kohn AD, Summers SA, Birnbaum MJ, Roth RA. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transpoter 4 translocation. J Biol Chem 49: 31372-31378, 1996. 51.Konutouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experiment model for cirrhosis in the rat. Br J Exp Pathol 65: 305-311, 1984. 52.Kovacs P, Stumvoll M. Fatty acids and insulin resistance in muscle and liver. Best Pract Res Clin Endocrinol Metab 19: 625-635, 2005. 53.Krook A, Bell JA, Robertson ME, Brueton L, O''Rahilly S. Prenatal analysis of the insulin receptor gene in a family with leprechaunism. Prenat Diagn 15: 669-671, 1995. 54.Laleman W, Elst V, Zeegers M, Servaes R, Libbrecht L, Roskams T, Fevery J, Nevens F. A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited. Eur J Clin Invest 36: 242-249, 2006. 55.Leatherdale BA, Chase RA, Rogers J, Alberti KG, Davies P, Record CO. Forearm glucose uptake in cirrhosis and its relationship to glucose tolerance. Clin Sci 59: 191-198, 1980. 56.Lebovitz HE. Rationale for and role of thazolidinediones in type 2 diabetes mellitus. Am J Cardiol 90: 34-41, 2002. 57.Lebrec D and Blanchet L. Effect of two models of portal hypertension on splanchnic organ blood flow in the rat. Clin Sci (Lond) 68: 23-28 1985. 58.Ledda-Columbano GM, Coni P, Curto M, Giacomini L, Faa G, Oliverio S, Piacentini M, Columbano A. Induction of two different models of cell death, apoptosis and necrosis, in rat liver after a single dose of thioacetamide. Am J Pathol 275: 1099-1109, 1991. 59.Lee FY and Groszmann RJ. Experiment models in the investigation of portal hypertension. Acities Ren Dysfunct Liv Dis Pathog Diagn Treat 1: 365-78, 1999. 60.Lee JW, Shin KD, Lee M, Kim E, Han SS, Han MY, Ha HJ, Jeong TC, Koh WS. Role of metabolism by flavin-containing monooxygenase in thioacetamide-induced immunosuppression. Toxicol Lett 136: 163-172, 2003. 61.Lindquist JN, Marzluff WF, and Stefanovic B. Fibrogenesis. III. Posttranscriptional regulation of type I collagen. Am J Physiol Gastrointest Liver Physiol 279: G471-G476, 2000. 62.Low TY, Leow CK, Salto-Tellez M, Chung MCM. A proteomic analysis of thiacetamide-induced hepatotoxicity and cirrhosis in rat livers. Proteomics 4: 3960-3974, 2004. 63.Luper S. A review of plants used in treatment of liver disease: Part I. Altern Med Rev 3: 410-21, 1998. 64.Marra F, Arrighi MC, Fazi M, Caligiuri A, Pinzani M, Romanelli RG, Efsen E, Laffi G, Gentilini P. Extracellular signal-regulated kinase activation differentially regulates platelet derived growth factor's actions in hepatic stellate cells, and is induced by in vivo liver injury in the rat. Hepatology 30: 951-958, 1999. 65.Maher JJ, Zia S, Tzagarakis C. Acetaldehyde- induced stimulation of collagen synthesis and gene expression is dependent on conditions of cell culture: studies with rat lipocytes and fibroblasts. Alcohol Clin Exp Res 18: 403-409, 1994. 66.Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, Bonacchi A, Caporale R, Laffi G, Pinzani M, Gentilini P. Ligands of peroxisome proliferator- activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119: 466-478, 2000. 67.Marra F. Chemokines in liver inflammation and fibrosis. Front Biosci 7: d1899-d1914, 2002. 68.Marra, F. Leptin and liver fibrosis: a matter of fat. Gastroenterology 122: 1529-1532, 2002. 69.McCay PB, Lai EK, Poyer JL, DuBose CM, Janzen EG. Oxygen- and carbon-centered free radical formation during carbon tetrachloride metabolism. Observation of lipid radicals in vivo and in vitro. J Biol Chem 259: 2135-2143, 1984. 70.Melloul D. Role of NF-kappaB in beta-cell death. Biochem Soc Trans 36: 334-339, 2008. 71.Mertz W. Chromium in human nutrition: a review. J Nutr 123: 626-633, 1993. 72.Mertz W, Schwarz JB. Relation of glucose tolerance factor to impaired intravenous glucose tolerance of rats onstock diets. Am J Physiol 196: 614-678, 1959. 73.Mertz W. Effects and metabolism of glucose tolerance factor. Nutr Rev 33: 129-135, 1975. 74.Miguez MP, Anundi I, sainz-Pardo LA, Lindros KO. Hepatoprotective mechanism of silymarin: no evidence for involvement of cytochrome P4502E1. Chem Biol Interact 91: 51-63, 1994. 75.Miller AL. Antioxidant flavonoids: Structure, function and clinical usage. Altern Med Rev 1: 103-111, 1996. 76.Morland CM, Fear G, McNab G, Joplin R, Adams DH. Promotion of leukocyte transendothelial cell migration by chemokines derived from human biliary epithelial cells in vitro. Proc Assoc Am Physicians 109: 372-382, 1997. 77.Morris BW, Gray TA, MacNeil S. Glucose-dependent uptake of chromium in human and rat insulin-sensitive tissue. Clin Sci 84: 477-482, 1993. 78.Munter K, Mayer D, Faulstich H. Characterization of a transporting system in rat hepatocytes: studies with competitive and non-competitive inhibitors of phalloidin transport. Biochem Biophys Acta 860: 91-98, 1986. 79.Muriel P, Mourelle M. Prevention by silymarin of membrane alteration in acute CCl4 liver damage. J Appl Toxicol 10: 275-279, 1990. 80.Naito M, Hasegawa G, Ebe Y, Yamamoto T. Differentiation and function of Kupffer cells. Med Electron Microsc 37: 16-28, 2004. 81.Nielsen FH. Chromium. In: Shils ME, Olson JA, Shike M, eds. Mondern nutrition in health and disease. Philadelphia: Lea and Febiger. 264-268, 1994. 82.Nolte W, Hartmann H, Ramadori G. Glucose metabolism and liver cirrhosis. Exp Clin Endocrinol Diabetes 103: 63-74, 1995. 83.Oben JA, Roskams T, Yang S, Lin H, Sinelli N, Torbenson M, Smedh U, Moran TH, Li Z, Huang J, Thomas SA, Diehl AM. Hepatic fibrogenesis requires sympathetic neurotransmitters. Gut 53: 438-445, 2004. 84.Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 97: 2408-2414, 2002. 85.Muriel P, Moreno MG, Hernández Mdel C, Chávez E, Alcantar LK. Resolution of liver fibrosis in chronic CCl4 administration in the rat after discontinuation of treatment: effect of silymarin, silibinin, colchicine and trimethylcolchicinic acid. Basic Clin Pharmacol Toxicol 96: 375-380 2004. 86.Patti ME, Kahn CR. The insulin receptor-α critical link in glucose homeostasis and insulin action. J Basic Clin Physiol Pharmacol 9: 89-109, 1998. 87.Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, Angus PW. Up-regulation of components of the renin-angiotensin system in the bile ductligated rat liver. Gastroenterology. 123: 1667-1676, 2002. 88.Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 106: 165-169, 2000. 89.Petetmann H, Vogl S, Schulze E, Dargel R. Chronic liver injury alters basal and stimulated nitric oxide production and 3H-thymidine incorporation in culture sinusoidal endothelial cells from rats. J Hepatol 31: 284-292, 1999. 90.Pizani M, Gesualdo L, Sabbah GM, Abboud HE. Effects of Platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of culture rat liver fat-stroring cells. J Clin Invest 84: 1786-1793, 1989. 91.Pinzani M. Liver fibrosis. Springer Semin Immunopathol 21: 475-490, 1999. 92.Pinzani M. PDGF and signal transduction in hepatic stellate cells. Front Biosci 7: d1720-d1726. 107, 2002. 93.Porter WR, Neal RA. Metabolism of thioacetamide and thioacetamide-S-oxide by rat liver microsomes. Drug Metab Dispos 6: 379-388, 1978. 94.Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 124: 491-504, 2006. 95.Ramadori G, Saile B. Portal tract fibrogenesis in the liver. Lab Invest 84: 153-159, 2004. 96.Rippe RA, Schrum LW, Stefanovic B, Solis- Herruzo JA, Brenner DA. NF-kappaB inhibits expression of the alpha1 (I) collagen gene. DNA Cell Biol 8: 751-761, 1999. 97.Rondinone CM, Wang LM, Lonnroth P, Wesslau C, Pierce JH, Smith U. Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinostiol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 94: 4171-4175, 1997. 98.Rondinone CM, Carvalho E, Wesslau C, Smith UP. Impaired glucose transport and protein kinase B activation by insulin, but not okadaic acid, in adipocytes from subjects with Type II diabetes mellitus. Diabetologia 42: 819-825, 1999. 99.Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver disease. Drugs 61: 2035-2063, 2001. 100.Saliou C, Rihn B, Cillard J, Okamoto T, Packer L. Selective inhibition of NF-κB activation by the flavonoid hepatoprotector silymarin in HepG2. FEBS Lett 440: 8-12, 1998. 101.Saltiel AR, Kahn C. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 414: 799-806, 2001. 102.Sanger F. The terminal peptides of insulin. Biochem J 45: 563-574, 1949. 103.Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA.The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 34: 89-100, 2001. 104.Schwarz K, Mertz W. A glucose tolerance factor and its differentiation from factor 3. Arch Biochem Biophys 72: 515-518, 1957. 105.Schwarz K, Mertz W. Chromium(III) and the glucose tolerance factor. Arch Biochem Biochem Biophys 85: 292-295, 1959. 106.Selberg O, Burchert W, Hoff J, Meyer GJ, Hundeshagen H, Radoch E, et al. Insulin resistance in liver cirrhosis. Positronemission tomography scan analysis of skeletal muscle glucose metabolism. J Clin Invest 91: 1897-1902, 1993. 107.Shek FW, Benyon RC. How can transforming growth factor beta be targeted usefully to combat liver fibrosis? Eur J Gastroenterol Hepatol 16: 123-126 2004. 108.Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signaling. Biochem J 333: 471-490, 1998. 109.Sherlock S, Dooley J. Diseases of liver and biliary system. 11th ed. Oxford: Blackwell scientific Publications 322-356, 2002. 110.Sonnenbichler J, Zetl I. Biochemical effects of theflavonolignan silibinin on RNA, protein, and DNA synthesis in rat liver. Progr Clin boil Res 213: 319-331, 1986. 111.Stoecker BJ. Chromium. In: Brown ML, ed. Present knowledge in nutriton. International Life Sciences Institute Nutrition Foundation. Washington, USA. Pp. 287-293, 1990. 112.Strazzabosco M, Spiril C, Okolicsanyi. Pathophysiology of the intrahepatic biliary epithelium. J Gastroenterol Hepatol 15: 244-253, 2000. 113.Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signaling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7: 85-96, 2006. 114.Thurman RG. II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Physiol 275:G605-G611, 1998. 115.Torres MI, Fernandez MI, Gil A, Rios A. Dietary nucleotides have cytoprotective properties in rat liver damaged by thioacetamide. Life Sci 62: 13-22, 1998. 116.Tsukada S, Westwick JK, Ikejima K, Sato N, Rippe RA. SMAD and p38 MAPK signaling pathways independently regulate alpha1(I) collagen gene expression in unstimulated and transforming growth factor-beta-stimulated hepatic stellate cells. J Biol Chem 280: 10055-10064, 2005. 117.Tsukamoto H, Matsuoka M, French SW. Experimental models of hepatic fibrosis: a review. Semin Liv Dis: 10, 56-65, 1990. 118.Vestergaard H, Bjørbaek C, Hansen T, Larsen FS, Granner DK, Pedersen O. Impaired activity and gene expression of hexokinase II in muscle from non-insulin-dependent diabetes mellitus patients. J Clin Invest 96: 2639-2645, 1995. 119.Vestergaard H, Lund S, Larsen FS, Bjerrum OJ, Pedersen O. Glycogen synthase and phosphofructokinase protein and mRNA levels in skeletal muscle from insulin-restant patients with non-insulin-dependent diabetes mellitus. J Clin Invest 91: 2342-2350, 1993. 120.Walker KS, Deak M, Paterson A, Hudson K, Cohen P,Alessi DR. Activation of protein kinase β and γ isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison with protein kinase Bα. Biochem J 331: 299-308, 1998. 121.Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 24: 99-106, 2004. 122.Waters NJ, Waterfield CJ, Farrant RD, Holmes E, Nicholson JK. Metabonomic deconvolution of embedded toxicity: application to thioacetamide hepato- and nephrotoxicity. Chem Res Toxicol 18: 639-654, 2005. 123.Wheeler MD, Kono H, Yin M, Nakagami M, Uesugi T, Arteel GE, Gäbele E, Rusyn I, Yamashina S, Froh M, Adachi Y, Iimuro Y, Bradford BU, Smutney OM, Connor HD, Mason RP, Goyert SM, Peters JM, Gonzalez FJ, Samulski RJ, Thurman RG. The role of Kupffer cell oxidant production in early ethanol-induced liver disease. Free Radic Biol Med 31: 1544-1549, 2001. 124.White MF, Kahn CR. The insulin signaling system. J Biol Chem 269: 1-4, 1994. 125.Williams EJ, Benyon RC, Trim N. Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut 49: 577-583, 2001. 126.Wiseman H. Dietary influences on membrane function: Importance in ptotection against oxidative damage and disease. J Nutr Biochem 7: 2-5, 1996. 127.Yamanoto A, Wada O, Ono T. Isolation of a biologically active low-molecular-mass chromium compound from rabbit liver. Eur J Biochem 165: 627-631, 1987.
摘要: 
本實驗利用腹腔注射硫代乙醯氨(thioacetamide, TAA, 200 mg/kg)誘導肝硬化動物模式,評估TAA引發肝硬化動物胰島素阻抗之影響,並探討silymarin (60mg/隻)對肝硬化動物之保肝效果是否有部分來自於改善胰島素的作用。經TAA誘導10週後SD大鼠的肝臟經Sirius red染色及測定肝中hydroxyprolin含量,顯示連續給予TAA 10週後可引發肝纖維化,同時給予silymarin可改善纖維化的現象;在肌肉的Akt總量表現上三組並沒有明顯的差異,但是在TAA+silymarin組肌肉的Akt-ser473磷酸化顯著的高於TAA組 (P<0.05);分析 HOMA%B (胰臟β細胞的功能),發現TAA組其HOMA%B (μU/mmol)有下降的趨勢。由上述結果得知,連續給予TAA 10週後可引發肝纖維化,並造成胰臟β細胞分泌胰島素的功能下降,而胰島素之作用同時減少,而藉由silymarin的給予能改善TAA肝硬化動物胰島素組抗的情形。

In this study, we attempt to determine the effect of silymarin in rats on
liver cirrhosis and insulin resistance. Rats were divided into a TAA, TAA+silymarin-treated, and control group. Treatment with TAA in rats by twice a week for 10 weeks were found liver cirrhosis compared to control group. However, TAA+silymarin caused a decrease in fibrosis production of liver. Moreover, there is no different expression of total Akt among TAA-, TAA+silymarin-treated, and control group. Continuously, rats treatment with TAA+silymarin showed an increase in expression of Akt-pSer473, however, HOMA%B was decreased in TAA-treated rats. These results indicated that administrated of TAA showed a decrease in insulin secretion, and silymarin may increase insulin sensitivity in TAA-induced liver cirrhosis rats.
URI: http://hdl.handle.net/11455/13566
其他識別: U0005-1808200802441700
Appears in Collections:獸醫學系所

Show full item record
 

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.